Beqvez

Search documents
被嫌弃的AAV病毒递送系统
3 6 Ke· 2025-10-09 23:18
安全性问题频出,Sarepta的AAV基因疗法Elevidys因患者死亡事件被FDA勒令暂停销售,Capsida Biotherapeutics公司的AAV相关临床试验也因儿童患者死 亡被迫中止。 加之"天价"问题,商业化局面迟迟难以打开,近一年来,AAV基因治疗领域退潮信号愈发强烈:今年2月,辉瑞宣布终止最后一个AAV项目Beqvez;5月, 福泰制药明确表示不再将AAV用作基因治疗项目的递送机制;9月底,渤健更是宣布直接清空了全部AAV管线。 昔日炙手可热的AAV赛道,突然间弥漫着撤退、危险的气息,这与几年前的盛况形成了鲜明对比。 作为曾经的明星载体,AAV成功助推了一批划时代的基因疗法问世,也吸引着无数biotech与大药企的押注。 然而,随着临床深入与商业落地加速,AAV的隐患无处遁形:高剂量毒性、免疫应答失控、天价成本……AAV载体一步步滑落神坛,甚至被大药企纷 纷"嫌弃"、抛弃。 困境,远比想象中更残酷。从被争相追逐的"黄金工具",到被质疑甚至放弃的递送系统,AAV载体未来何去何从? 三大硬伤 基因治疗草莽初创之际,其他递送系统尚存在诸多不成熟因素,AAV以其特性——结构稳定、表达持久、较低的免疫 ...
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
The Motley Fool· 2025-06-12 09:00
Core Viewpoint - Dividend income is a valuable strategy for enhancing financial stability and potentially reducing dependence on employment income, which can lead to a more fulfilling life [1] Group 1: High-Yielding Dividend Stocks - Pfizer is highlighted as a long-term investment option with a current yield of 7.4%, significantly higher than the S&P 500 average of 1.3% [4] - Despite a decline of over 10% in stock price this year, Pfizer's valuation remains modest at 17 times trailing earnings, with revenue guidance between $61 billion and $64 billion for the year [5][6] - Realty Income is a recommended REIT with a high yield of 5.8% and monthly dividend payments, providing a consistent cash flow for investors [8] - Realty Income reported funds from operations (FFO) per share of $1.05, up from $0.94 a year ago, supporting its dividend payout [9][10] - Bank of Nova Scotia offers a high dividend yield of around 6%, with a strong historical track record of regular payments since 1833 [11] - The bank's net income was over 2 billion Canadian dollars for the quarter ending April 30, showing stability despite macroeconomic concerns [12] - Scotiabank has increased its dividend by more than 22% over the past four years, making it a solid long-term investment option [13]
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
Globenewswire· 2025-05-13 13:00
Core Insights - Capricor Therapeutics has appointed Dr. Michael Binks as Chief Medical Officer, effective immediately, to lead the advancement of deramiocel for Duchenne muscular dystrophy (DMD) and future pipeline opportunities [1][2] - Dr. Binks has 25 years of experience in clinical development and has held senior roles at Pfizer and GlaxoSmithKline, contributing to the advancement of several first-in-class therapies [2] - Capricor's lead product candidate, deramiocel, is in late-stage development and has shown potent immunomodulatory and anti-fibrotic actions in preserving cardiac and skeletal muscle function in dystrophiopathies [3] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with a commitment to innovative treatments [3] - The company has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of deramiocel for DMD in the United States and Japan, pending regulatory approval [6]
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
The Motley Fool· 2025-04-30 11:05
Market Overview - The S&P 500 has declined approximately 6% since the beginning of the year, with a more significant drop earlier in April when global tariffs were announced [1] - Despite a recent recovery, the risk of further market sell-offs remains [1] Investment Opportunities - Long-term investors may find buying opportunities in stocks that are down over 10% this year and trading at low earnings multiples, specifically Pfizer, PayPal, and Builders FirstSource [2] Pfizer - Pfizer's stock has decreased by 13% in 2025, with expectations of nearly unchanged or declining revenue for the year [3][4] - The company trades at a forward P/E multiple of less than 8 and aims to add $25 billion in revenue through in-house development and acquisitions despite potential losses of $18 billion from generics by the end of the decade [4] - Recent acquisitions, including oncology company Seagen, are expected to contribute up to $10 billion in revenue by the end of the decade [5] - Pfizer's mRNA pipeline is projected to generate between $10 billion and $15 billion by 2030, and the company has over 100 drug candidates in clinical trials [6] - The stock offers a dividend yield of over 7%, making it an attractive long-term investment [7] PayPal - PayPal's stock is down more than 20% this year and trades at only 13 times its future earnings, with concerns about a global economic slowdown affecting its growth prospects [8] - The company holds a significant position in the global payments market, accounting for nearly 45% of it, and is well-positioned for long-term recovery [9] - PayPal is expanding into the crypto market with the launch of PayPal USD, offering a 3.7% yield to attract investors, which could drive more transactions and revenue growth [10] - The company's payment volume rose by 10% last year, indicating potential for long-term investment despite short-term concerns [11] Builders FirstSource - Builders FirstSource trades at a forward P/E of less than 13 and plays a vital role in the homebuilding industry [12] - The company experienced a 4% decline in sales in 2024, totaling $16.4 billion, but is expected to benefit from long-term housing market growth [13] - Builders FirstSource has grown significantly from $8.6 billion in sales in 2020, aided by acquisitions and a strong housing market [14] - The company invested $352 million in 13 acquisitions last year and projects a net sales growth of 4% to 4.5% from these acquisitions [15] - Despite a 15% decline in stock price this year, Builders FirstSource remains a strong long-term investment [16]